Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Basal-like breast cancer (BLBC) is resistant to endocrinotherapy and targeted therapy and new molecular therapies are needed for BLBC. In this study, we evaluated the role of DUSP1 and DUSP5, negative regulators of mitogen-activated protein kinase pathway, in the aggressiveness of BLBC. | The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer